July 18, 2011
Adis Journals Make Impressive Impact Factor Gains
YARDLEY, Pa., July 18, 2011 /PRNewswire/ -- Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to pharmaceutical and healthcare professionals, today announced strong impact factor (IF) gains for its Adis line of drug therapy and patient management journals. 11 of the 13 Adis journals that carried IFs in 2009 bettered their performance in 2010 according to the annual Journal Citation ReportsÃ® published in June.
The most impressive gains over 2009 were made by PharmacoEconomics (IF 3.44) - up 34 percent to become the leading Health Outcomes Research journal, and Sports Medicine (IF 5.072) - up 63 percent, also becoming the highest ranking title in its field.Drugs in R&D (IF 1.707), re-launched in 2010 as Adis' first fully open access MEDLINE-indexed journal gained 26 percent. Other standout performers include CNS Drugs (IF 4.497) - up 16 percent and Biodrugs (IF 4.192) - up 20 percent.
"The price of Adis journals was significantly restructured at the end of 2009 providing affordable access for a wider group of customers," said Iain Spray, Adis Product Manager, Wolters Kluwer Pharma Solutions. "These IF gains are partly the result of that increased access, and the continued determination of our editors, editorial boards and publishing team to strive for the highest level of quality."
An impact factor quantifies the relative influence of a scholarly journal in its scientific field. It is a measure of the frequency with which the average article in a journal has been cited in a given year.
For more than 40 years, medical and scientific researchers have turned to Adis for its high quality, peer-reviewed content. Adis journals, covering the evidence-based pharmacology spectrum from clinical pharmacology to drug development and drug safety, to pharmacoeconomics, medical biotechnology and disease management, are available on AdisOnline (http://adisonline.com).
For more information, visit the company's website at www.wolterskluwerpharma.com.
About Wolters Kluwer Pharma Solutions
Wolters Kluwer Pharma Solutions, Inc. (Phoenix, AZ and Yardley, PA) is a leading provider of information and analytics to the pharmaceutical, biotech, and medical device industries. The company's brands include Adis, SourceÃ® and Lippincott Williams & Wilkins. A provider of business intelligence and services, Adis publishes 19 peer-reviewed drug research journals and 2 newsletters and offers the most respected drug and clinical trials databases in the pharma industry. Lippincott Williams & Wilkins (LWW) is a leading international healthcare publisher with nearly 300 periodicals and 1,500 books in more than 100 disciplines. A longstanding provider of market data and healthcare analytics, SourceÃ® offers a unique set of comprehensive patient and physician-level prescribing and usage data. For more information, visit www.wolterskluwerpharma.com.
The company is a wholly owned subsidiary of Wolters Kluwer, U.S., part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer's leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer has 2010 annual revenues of euro 3.6 billion ($4.7 billion), employs approximately 18,200 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.
Contact: Tom Kivett Kivett & Company Communications +1 212 727-2935 [email protected]
SOURCE Wolters Kluwer Pharma Solutions, Inc.